Aurenar gets FDA breakthrough nod for noninvasive neuromod tech
June 30, 2026
Aurenar announced today that it received FDA breakthrough device designation for its V-Link noninvasive neuromodulation system.
Aurenar announced today that it received FDA breakthrough device designation for its V-Link noninvasive neuromodulation system.
Novocure (Nasdaq:NVCR) announced today that its Optune Pax device for treating pancreatic cancer received CE mark approval.
StarMed announced today that it received FDA 510(k) clearance for its platform that delivers radiofrequency (RF) ablation of thyroid nodules.
MINNEAPOLIS, June 29, 2026 /PRNewswire/ — Laplace Interventional today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for TRIUMPH, the company’s pivotal trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system.
IntelliGenome, Inc., a molecular diagnostics company advancing next-generation tuberculosis detection technologies, today announced that Colombia’s National Institute for Food and Drug Surveillance (INVIMA) has granted sanitary registration for the CRISPR-TB Blood Test Kit.
Edwards Lifesciences (NYSE:EW) has earned FDA 510(k) clearance for Ecliptis, its left atrial appendage (LAA) exclusion system.
Artivion (NYSE:AORT) announced today that it received FDA premarket approval (PMA) for its AMDS Hybrid Prosthesis device.
United Therapeutics (Nasdaq:UTHR) announced today that the FDA granted premarket approval (PMA) for its LungFX perfusion device.
Bioness Medical announced today that it received FDA 510(k) clearance for its PoNS (portable neuromodulation stimulator) system.
Michigan State University researchers have identified how ovarian cancer cells become resistant to chemotherapy and discovered a protein that, when blocked, can restore the drug’s effectiveness.